Our study demonstrated that inhibition of AR signaling decreases activation of the NGF–CHRM4 axis, which is associated with neuroendocrine differentiation of prostate cancer, suggesting that current hormonal therapy designed to suppress AR functions may predispose prostate cancer to NEPC development. This evidence concerns the gene AR and prostate carcinoma.